3 MedTech Stocks to Buy as Monetary Policy Eases — Sep 30th, 2024

MedTech manufacturers, who were literally hankering for the easing of monetary policy following a prolonged period of challenging business scenarios, probably heaved a sigh of relief after September’s aggressive rate cut. The highly-anticipated 50-bps rate cut by the Fed, bringing the fe...

New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men — Oct 2nd, 2024

Findings are from the prospective, multicenter VANDAAM trial SOUTH SAN FRANCISCO, Calif., October 02, 2024--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new data from the multicenter, prospective VANDAAM trial show that the Decipher ...

Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today — Oct 4th, 2024

How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well. Another thing that can drive investing is the fear of missing ...

Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners — Sep 25th, 2024

Building a successful investment portfolio takes skill and hard work, no matter if you're a growth, value, income, or momentum-focused investor. Should You Buy #1 (Strong Buy)-Ranked Veracyte (VCYT) for Your Portfolio? Veracyte was upgraded to the Zacks Rank #1 list on August 14, 2024. T...

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick — Sep 25th, 2024

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, ...

Vanguard Group Inc's Strategic Acquisition of Veracyte Inc Shares — Oct 2nd, 2024

Overview of the Recent Transaction On September 30, 2024, Vanguard Group Inc made a significant addition to its investment portfolio by acquiring 251,533 shares of Veracyte Inc (NASDAQ:VCYT), a leader in genomic diagnostics. This transaction increased Vanguard's total holdings in the comp...